Move to topTop
TOKYO, JAPAN – September 16, 2022 – Associates of Terumo Corporation (TSE: 4543) today celebrated “Terumo Patient’s Day 2022” to connect with Terumo’s Group Mission “Contributing to Society through Healthcare”, and for each associate to reconfirm their day-to-day contribution at work ultimately leads to the well-being of patients.

Terumo Patient’s Day originally started in 2013, and this is the ninth year of celebration. Terumo Patient’s Day is celebrated globally throughout the Terumo Group. Every year, various activities to engage with medical settings are held such as healthcare provider and patient speaker events, visits to hospitals, and blood donation drives.

For associates working at Terumo Corporation in Japan, in the past, events on themes such as cancer, heart disease, kidney disease, blood transfusion, and nursing have been held. This year, talk sessions on diabetes took place, featuring a doctor and a person with type 1 diabetes as speaker guests.  

Shinjiro Sato, CEO of Terumo Corporation comments, “Terumo has 28,000 steadfast associates gathered from around the world resonating with our Group Mission and Core Values. Many associates may not have direct interaction with medical settings in the course of daily work. But without a doubt, each of our jobs finds its way to patients, in the form of ‘solutions’ we provide through our products and services. I hope that each and every Terumo Associates feel proud and continue the very important work that each of us is responsible for. As a company, our Purpose is to advance healthcare and enhancing patients’ quality of life.”

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.